|
|
Article: Coley's Anti-Terrorism TLRs Get Another $16.9M Contract.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
The growing-hotter field of Toll-like receptors (TLRs) garnered another research contract from the National Institutes of Health for Coley Pharmaceutical Group Inc., this one for $16.9 million, to make drugs for defense against biological terrorism.
Titled "Innate Immune Receptors and Adjuvant Discovery," the contract from the National Institute of Allergy and Infectious Diseases (one of the NIH's institutes) brings to $35 million the total of such awards gained by Coley.
"We're not a vaccine company, and our strategy is to use the funding we get from sources like the government to expand our technology base, to the extent ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|